Tumor Volume Useful Beyond Classic Criteria in Selecting Larynx Cancers For Preservation Therapy.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Affiliation:
      Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland Ohio,, U.S.A.
      Taussig Cancer Institute
      Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland Ohio,, U.S.A.
    • Abstract:
      Objective: To investigate the association between tumor volume and locoregional failure (LRF) after concurrent chemoradiation (CCRT) for locally advanced larynx cancer (LC).Methods: This is a retrospective cohort study from 2009 to 2014 identified from an institutional review board-approved registry. Fifty-nine of 68 patients with locally advanced larynx cancer treated with definitive CCRT who had available imaging for review were identified. The main endpoint to be assessed was the association between gross tumor volumes (GTV; T = total, P = primary, N = nodal) and LRF. Receiver operative characteristic (ROC) curves were used to investigate diagnostic accuracy.Results: Twenty LRFs were observed, resulting in a 2-year LRF rate of 39% (95% CI, 23-52%). On UVA, the GTV-T (P = .01), GTV-P (P = .05), and GTV-N (P = .04) were statistically significant predictors of LRF. Furthermore, age, smoking status, N-stage, larynx subsite, and tracheostomy/feeding tube dependence were potentially associated with LRF (P < .3), whereas T-stage (T3-4 vs. T2) was not (HR 1.05, 95% CI, 0.38-2.91, P = .92). In the multivariable model, GTV-P (HR 1.022, 95% CI, 0.999-1.046, P = .07) and GTV-N (HR 1.053, 95% CI, 1.0004-1.108, P = .05) were the two most impactful covariates on the model's R2 . ROC analysis suggested an optimal cut point of 12 cc in the GTV-T. The 2-year LRF for GTV-T > 12 cc was 64.2% and ≤ 12 cc was 16.4%, P = .006.Conclusion: GTV is associated with LRF after definitive CCRT for LC. Patients with bulky primary and/or nodal tumors may be better served with upfront surgical resection regardless of T-stage. Further investigation into the safety of larynx preservation for low-volume T4 tumors can be considered.Level Of Evidence: 4 Laryngoscope, 130:2372-2377, 2020.
    • Journal Subset:
      Allied Health; Biomedical; Peer Reviewed; USA
    • ISSN:
      0023-852X
    • MEDLINE Info:
      PMID: NLM31721229 NLM UID: 8607378
    • Publication Date:
      In Process
    • Publication Date:
      20200927
    • DOI:
      10.1002/lary.28396
    • Accession Number:
      145697729
  • Citations
    • ABNT:
      SHARRETT, J. M. et al. Tumor Volume Useful Beyond Classic Criteria in Selecting Larynx Cancers For Preservation Therapy. Laryngoscope, [s. l.], v. 130, n. 10, p. 2372–2377, 2020. DOI 10.1002/lary.28396. Disponível em: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=rzh&AN=145697729. Acesso em: 24 nov. 2020.
    • AMA:
      Sharrett JM, Ward MC, Murray E, et al. Tumor Volume Useful Beyond Classic Criteria in Selecting Larynx Cancers For Preservation Therapy. Laryngoscope. 2020;130(10):2372-2377. doi:10.1002/lary.28396
    • APA:
      Sharrett, J. M., Ward, M. C., Murray, E., Scharpf, J., Lamarre, E. D., Prendes, B. L., Lorenz, R. R., Burkey, B. B., Koyfman, S. A., Woody, N. M., Greskovich, J. F., Adelstein, D. J., Geiger, J. L., & Joshi, N. P. (2020). Tumor Volume Useful Beyond Classic Criteria in Selecting Larynx Cancers For Preservation Therapy. Laryngoscope, 130(10), 2372–2377. https://doi.org/10.1002/lary.28396
    • Chicago/Turabian: Author-Date:
      Sharrett, Jonathan M., Matthew C. Ward, Eric Murray, Joseph Scharpf, Eric D. Lamarre, Brandon L. Prendes, Robert R. Lorenz, et al. 2020. “Tumor Volume Useful Beyond Classic Criteria in Selecting Larynx Cancers For Preservation Therapy.” Laryngoscope 130 (10): 2372–77. doi:10.1002/lary.28396.
    • Harvard:
      Sharrett, J. M. et al. (2020) ‘Tumor Volume Useful Beyond Classic Criteria in Selecting Larynx Cancers For Preservation Therapy’, Laryngoscope, 130(10), pp. 2372–2377. doi: 10.1002/lary.28396.
    • Harvard: Australian:
      Sharrett, JM, Ward, MC, Murray, E, Scharpf, J, Lamarre, ED, Prendes, BL, Lorenz, RR, Burkey, BB, Koyfman, SA, Woody, NM, Greskovich, JF, Adelstein, DJ, Geiger, JL & Joshi, NP 2020, ‘Tumor Volume Useful Beyond Classic Criteria in Selecting Larynx Cancers For Preservation Therapy’, Laryngoscope, vol. 130, no. 10, pp. 2372–2377, viewed 24 November 2020, .
    • MLA:
      Sharrett, Jonathan M., et al. “Tumor Volume Useful Beyond Classic Criteria in Selecting Larynx Cancers For Preservation Therapy.” Laryngoscope, vol. 130, no. 10, Oct. 2020, pp. 2372–2377. EBSCOhost, doi:10.1002/lary.28396.
    • Chicago/Turabian: Humanities:
      Sharrett, Jonathan M., Matthew C. Ward, Eric Murray, Joseph Scharpf, Eric D. Lamarre, Brandon L. Prendes, Robert R. Lorenz, et al. “Tumor Volume Useful Beyond Classic Criteria in Selecting Larynx Cancers For Preservation Therapy.” Laryngoscope 130, no. 10 (October 2020): 2372–77. doi:10.1002/lary.28396.
    • Vancouver/ICMJE:
      Sharrett JM, Ward MC, Murray E, Scharpf J, Lamarre ED, Prendes BL, et al. Tumor Volume Useful Beyond Classic Criteria in Selecting Larynx Cancers For Preservation Therapy. Laryngoscope [Internet]. 2020 Oct [cited 2020 Nov 24];130(10):2372–7. Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=rzh&AN=145697729